News

With the FDA’s approval, Voltaren Arthritis Pain becomes the first and only prescription strength, nonsteroidal anti-inflammatory (NSAID) topical gel for arthritis pain available OTC in the United States.

ASC41 is expected to be used in combination with ASC40, another innovative drug of the Company, for treatment of non-alcoholic steatohepatitis (NASH). ASC41 is an oral thyroid hormone

Beovu is claimed to be the first EC-approved anti-VEGF treatment to show better resolution of retinal fluid (IRF/SRF) against aflibercept. Wet AMD, a chronic and degenerative eye disease,

The company said that 26% of patients with previously treated advanced or metastatic renal cell carcinoma are alive at five years of treatment with Opdivo. According to Bristol-Myers

Results presented at The European Crohn’s and Colitis Organisation (ECCO) 2020 annual congress in Vienna, Austria demonstrated that the SC formulation of CT-P13 was comparable to the IV

Intestinal ultrasound (IUS) responses were assessed and were detected as early as week 4.2 Week 16 data (digital oral presentation or DOP 13) and IUS response data (DOP

The regulator has accepted the firm’s new drug application (NDA) for the accelerated approval of tazemetostat to treat patients with relapsed or refractory FL who have secured at

This NDA requests FDA approval of tucatinib in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients

The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of August 17, 2020. “There remains a critical need for additional therapies in large B-cell